Other than LCN2, numerous studies have shown the benefit of mitogen-activated protein kinase (MAPK) inhibitor annexin-1 in attenuating the microvascular complications of diabetes, namely nephropathy and cardiomyopathy, but their use in DR remains unknown (72). Here, ANXA1 is linked to diabetes mellitus.